JP2022507781A5 - - Google Patents
Info
- Publication number
- JP2022507781A5 JP2022507781A5 JP2021527836A JP2021527836A JP2022507781A5 JP 2022507781 A5 JP2022507781 A5 JP 2022507781A5 JP 2021527836 A JP2021527836 A JP 2021527836A JP 2021527836 A JP2021527836 A JP 2021527836A JP 2022507781 A5 JP2022507781 A5 JP 2022507781A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106091A JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769946P | 2018-11-20 | 2018-11-20 | |
| US62/769,946 | 2018-11-20 | ||
| PCT/US2019/062302 WO2020106780A1 (en) | 2018-11-20 | 2019-11-19 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106091A Division JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022507781A JP2022507781A (ja) | 2022-01-18 |
| JP2022507781A5 true JP2022507781A5 (https=) | 2022-11-29 |
| JPWO2020106780A5 JPWO2020106780A5 (https=) | 2022-11-29 |
| JP7702866B2 JP7702866B2 (ja) | 2025-07-04 |
Family
ID=69005818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527836A Active JP7702866B2 (ja) | 2018-11-20 | 2019-11-19 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
| JP2025106091A Pending JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106091A Pending JP2025138724A (ja) | 2018-11-20 | 2025-06-24 | Ｌｘｒアゴニストとしての使用のためのビス－オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12209180B2 (https=) |
| EP (2) | EP4428142A3 (https=) |
| JP (2) | JP7702866B2 (https=) |
| KR (1) | KR20210094568A (https=) |
| CN (1) | CN113382985A (https=) |
| AU (1) | AU2019384136B2 (https=) |
| BR (1) | BR112021009673A2 (https=) |
| CA (1) | CA3120528A1 (https=) |
| CL (1) | CL2021001308A1 (https=) |
| CO (1) | CO2021007581A2 (https=) |
| EA (1) | EA202191430A1 (https=) |
| ES (1) | ES2984190T3 (https=) |
| IL (1) | IL283313B2 (https=) |
| MA (1) | MA53455B1 (https=) |
| MX (1) | MX2021005822A (https=) |
| MY (1) | MY206542A (https=) |
| PH (1) | PH12021551153A1 (https=) |
| SG (1) | SG11202105175WA (https=) |
| WO (1) | WO2020106780A1 (https=) |
| ZA (1) | ZA202103431B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250114431A (ko) | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| CN112533951A (zh) | 2018-05-09 | 2021-03-19 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| MA53455B1 (fr) * | 2018-11-20 | 2022-11-30 | Regeneron Pharma | Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr |
| KR20240038138A (ko) * | 2020-07-13 | 2024-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 |
| CA3198294A1 (en) | 2020-11-10 | 2022-05-19 | Thomas Nittoli | Selenium antibody conjugates |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US20240408226A1 (en) * | 2021-11-02 | 2024-12-12 | Mabplex International Co., Ltd. | Antibody drug conjugate intermediate containing sn38 and its preparation method |
| CN115594766A (zh) * | 2021-12-30 | 2023-01-13 | 辽宁键凯科技有限公司（Cn） | 一种缀合物及用其制备的抗体偶联药物 |
| CN115505028A (zh) * | 2022-09-16 | 2022-12-23 | 辽宁键凯科技有限公司 | 一种分支型聚乙二醇连接子及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| WO2001041704A2 (en) * | 1999-12-13 | 2001-06-14 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US6908934B2 (en) | 2001-06-11 | 2005-06-21 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| EP1758651A2 (en) | 2004-06-24 | 2007-03-07 | Galapagos N.V. | Lxr agonists to promote bone homeostasis |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| KR20090094125A (ko) * | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| US8993628B2 (en) * | 2007-02-23 | 2015-03-31 | City Of Hope | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| KR20140037105A (ko) | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| CA2850096C (en) | 2011-10-14 | 2018-07-03 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| FI2911699T4 (fi) | 2012-10-23 | 2025-12-09 | Synaffix Bv | Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi |
| CN105848685B (zh) | 2013-12-16 | 2020-09-22 | 健泰科生物技术公司 | 拟肽化合物及其抗体药物偶联物 |
| CN106459055B (zh) | 2014-01-27 | 2019-11-01 | 辉瑞大药厂 | 双功能细胞毒类药剂 |
| KR102399277B1 (ko) | 2014-04-10 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| US20160324981A1 (en) * | 2015-05-08 | 2016-11-10 | The California Institute For Biomedical Research | Liver x receptor agonists and uses thereof |
| CA3001938A1 (en) * | 2015-11-04 | 2017-05-11 | Borealis Ag | A process for producing a multilayer laminate |
| WO2017147542A2 (en) | 2016-02-26 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| KR20250114431A (ko) | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| WO2018213082A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| CN112533951A (zh) | 2018-05-09 | 2021-03-19 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| MA53455B1 (fr) * | 2018-11-20 | 2022-11-30 | Regeneron Pharma | Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr |
-
2019
- 2019-11-19 MA MA53455A patent/MA53455B1/fr unknown
- 2019-11-19 CN CN201980089547.4A patent/CN113382985A/zh active Pending
- 2019-11-19 CA CA3120528A patent/CA3120528A1/en active Pending
- 2019-11-19 SG SG11202105175WA patent/SG11202105175WA/en unknown
- 2019-11-19 JP JP2021527836A patent/JP7702866B2/ja active Active
- 2019-11-19 US US17/295,420 patent/US12209180B2/en active Active
- 2019-11-19 AU AU2019384136A patent/AU2019384136B2/en active Active
- 2019-11-19 WO PCT/US2019/062302 patent/WO2020106780A1/en not_active Ceased
- 2019-11-19 MY MYPI2021002708A patent/MY206542A/en unknown
- 2019-11-19 EA EA202191430A patent/EA202191430A1/ru unknown
- 2019-11-19 BR BR112021009673A patent/BR112021009673A2/pt unknown
- 2019-11-19 KR KR1020217018084A patent/KR20210094568A/ko not_active Ceased
- 2019-11-19 IL IL283313A patent/IL283313B2/en unknown
- 2019-11-19 ES ES19827877T patent/ES2984190T3/es active Active
- 2019-11-19 EP EP24186656.5A patent/EP4428142A3/en active Pending
- 2019-11-19 MX MX2021005822A patent/MX2021005822A/es unknown
- 2019-11-19 EP EP19827877.2A patent/EP3883926B1/en active Active
-
2021
- 2021-05-19 CL CL2021001308A patent/CL2021001308A1/es unknown
- 2021-05-20 PH PH12021551153A patent/PH12021551153A1/en unknown
- 2021-05-20 ZA ZA2021/03431A patent/ZA202103431B/en unknown
- 2021-06-10 CO CONC2021/0007581A patent/CO2021007581A2/es unknown
-
2024
- 2024-12-16 US US18/983,183 patent/US20250171622A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106091A patent/JP2025138724A/ja active Pending